Eli Lilly and Company (NYSE:LLY) Trading Up 1.1% – Here’s What Happened

Shares of Eli Lilly and Company (NYSE:LLY) rose 1.1% during trading on Monday . The stock traded as high as $1,170.90 and last traded at $1,165.62. 2,200,005 shares changed hands during trading, a decline of 27% from the average session volume of 3,018,681 shares. The stock had previously closed at $1,152.93.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CEO Dave Ricks said approximately 700,000 seniors have started GLP-1 treatments since Medicare coverage began, with Lilly capturing about 70% of new senior patients. Foundayo also represents roughly one-third of new oral GLP-1 prescriptions, suggesting significant commercial potential as coverage expands. Lilly Medicare GLP-1 coverage update
• Positive Sentiment: Lilly broke ground on a $6.5 billion Houston manufacturing facility that will produce active pharmaceutical ingredients for medicines including Foundayo. The project is expected to create more than 600 jobs and strengthen U.S. supply capacity, helping address potential demand constraints. Houston manufacturing facility announcement
• Positive Sentiment: The FDA granted full approval to Inluriyo in combination with Verzenio for advanced ESR1-mutated breast cancer after data showed a substantial progression-free-survival benefit, adding another growth opportunity beyond the obesity franchise. Inluriyo FDA approval
• Positive Sentiment: Investor sentiment was supported by bullish commentary from billionaire investor Ken Langone, who said LLY could reach $2,000 within three to four years. Analysts also continue to view Lilly favorably following its recent earnings beat and strong revenue growth. Ken Langone Lilly outlook
• Neutral Sentiment: Lilly indicated interest in purchasing up to $100 million of Oura shares in its IPO. The investment could support LillyDirect’s digital-health tools for patients using GLP-1 medicines, but its direct financial impact on LLY is likely limited. Oura IPO and Lilly investment
• Negative Sentiment: Viking Therapeutics posted encouraging data for VK2735, including potential advantages in weight maintenance and less-frequent dosing. The results heightened concerns that future competitors could challenge Lilly’s Zepbound franchise. Viking obesity drug data
• Negative Sentiment: Novo Nordisk reported Phase 3 data suggesting CagriSema outperformed a lower dose of tirzepatide in diabetes, reinforcing competitive pressure even as Lilly retains a leading position in the GLP-1 market. Novo CagriSema study

Analyst Ratings Changes

LLY has been the subject of a number of research analyst reports. Jefferies Financial Group increased their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Berenberg Bank set a $1,400.00 price objective on Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, September 15th. Bank of America upped their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Leerink Partners lifted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Finally, HSBC boosted their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research note on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,305.25.

Eli Lilly and Company Price Performance

The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The stock’s 50 day moving average price is $1,176.84 and its two-hundred day moving average price is $1,079.50. The firm has a market capitalization of $1.09 trillion, a price-to-earnings ratio of 39.00, a PEG ratio of 1.44 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same period last year, the business posted $6.31 EPS. Eli Lilly and Company’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 36.54 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 in the last 90 days. 0.14% of the stock is owned by company insiders.

Institutional Trading of Eli Lilly and Company

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after acquiring an additional 1,046,558 shares during the period. State Street Corp raised its holdings in Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after acquiring an additional 605,752 shares in the last quarter. Capital World Investors lifted its position in shares of Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after acquiring an additional 61,851 shares during the period. Norges Bank bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $12,976,634,000. Finally, Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $13,522,666,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.